PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2022.02082022284806-809Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex traitCarlos J. Pirola, Silvia Sookoianhttp://e-cmh.org/upload/pdf/cmh-2022-0208.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2022.0208, http://e-cmh.org/upload/pdf/cmh-2022-0208.pdf
Journal of Gastroenterology and Hepatology10.1111/j.1440-1746.2011.07018.x20122758-64Pathophysiology guided treatment of nonalcoholic steatohepatitisTuyet A T Nguyen, Arun J Sanyalhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1440-1746.2011.07018.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1440-1746.2011.07018.x/fullpdf
Drugs in R&D10.1007/s40268-015-0083-y201515113-20Auranofin: Repurposing an Old Drug for a Golden New AgeChristine Roder, Melanie J. Thomsonhttp://link.springer.com/article/10.1007/s40268-015-0083-y/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40268-015-0083-y.pdf, http://link.springer.com/content/pdf/10.1007/s40268-015-0083-y
Metabolism10.1016/j.metabol.2016.05.01320166591297-1306Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic reviewStergios A. Polyzos, Christos S. Mantzoroshttps://api.elsevier.com/content/article/PII:S0026049516300348?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0026049516300348?httpAccept=text/plain
Biochemical Pharmacology10.1016/0006-2952(87)90715-51987365647-654Cellular interactions of auranofin and a related gold complex with raw 264.7 macrophagesRosanne M. Snyder, Christopher K. Mirabelli, Stanley T. Crookehttps://api.elsevier.com/content/article/PII:0006295287907155?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:0006295287907155?httpAccept=text/plain
Journal of Digestive Diseases10.1111/1751-2980.1283020192113-11Development of new drugs for the treatment of nonalcoholic steatohepatitisJie Ting Tang, Yi Min Maohttps://onlinelibrary.wiley.com/doi/pdf/10.1111/1751-2980.12830, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/1751-2980.12830, https://onlinelibrary.wiley.com/doi/pdf/10.1111/1751-2980.12830
Expert Opinion on Investigational Drugs10.1080/13543784.2020.17039482019292163-178Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)Daren R. Ure, Daniel J. Trepanier, Patrick R. Mayo, Robert T. Fosterhttps://www.tandfonline.com/doi/pdf/10.1080/13543784.2020.1703948
Drug Repurposing - Molecular Aspects and Therapeutic Applications10.5772/intechopen.1013972022Repurposing Market Drugs to Target Epigenetic Enzymes in Human DiseasesAishat Motolani, Matthew Martin, Steven Sun, Tao Luhttp://www.intechopen.com/download/pdf/79461
International Journal of Molecular Sciences10.3390/ijms23147894202223147894Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0Mariapia Vairetti, Giuseppe Colucci, Andrea Ferrignohttps://www.mdpi.com/1422-0067/23/14/7894/pdf
Gastroenterology10.1016/s0016-5085(08)63642-220081344A-780S1900 Mitochondrial Complex III Is Decreased in Morbidly Obese Patients with Nonalcoholic SteatohepatitisKamran Qureshi, Michelle S. Johnson, Ronald H. Clements, Gary A. Abrams, Aimee L. Landarhttps://api.elsevier.com/content/article/PII:S0016508508636422?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508508636422?httpAccept=text/plain